Looking for biologic drug patents? See BiologicPatentWatch.com

DrugPatentWatch

Pharmaceutical Companies Facing the Most Expirations in 2016

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$2,495/ year
$495/ month

Premium Plan

$1,995/ year
$445/ month

Basic Plan

$1,195/ year
$295/ month

Drug companies facing the most patent expirations in 2016
Share:

This chart shows which pharmaceutical companies face the most patent expirations this year. The drug companies facing the most patent expirations this year are Takeda Pharms Usa, Santarus Inc, Celgene, Sanofi Aventis Us, Boehringer Ingelheim, Astrazeneca Pharms, Bayer Healthcare Llc, Abbvie, Allergan, and Glaxosmithkline.

« Back to Innovation Infographics

Database Preview

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2016 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc